Jim Cramer's Stop Trading: Speculation Isn't Bad

NEW YORK (TheStreet) -- TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, responded to Federal Reserve Chair Janet Yellen. In a Congressional hearing on Tuesday, Yellen called small-cap biotechnology stocks and small-cap social media stocks overvalued. 

On CNBC's "Cramer's Stop Trading" segment, he suggested that Yellen should have Regulation T levels raised if she believes there's too much speculation. The move would crimp down the amount of leverage given to investors. 

"I don't think there is [too much leverage]. I think people have a right to speculate with some of their money," Cramer argued, "and they have a right to lose money." 

How Apple's Big Deal With IBM Hurts BlackBerry and Microsoft

10 Best Cars for the Great American Road Trip

Intel Soars: What Wall Street Thinks

Time Warner Skyrockets as 21st Century Fox Confirms Rejected Bid

Acquisitions by Gilead Sciences (GILD) and Merck (MRK) have resulted in large premiums being paid for certain small-cap biotech stocks. But those acquisitions are boosting sales and the companies' portfolios of treatment options. 

In regards to Facebook (FB), the company trades with a somewhat reasonable valuation, given its projected growth, Cramer concluded. 

-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS held FB.

If you liked this article you might like

These Stocks Pay You to Own Them

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition